Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Rhea-AI Summary
Tonix Pharmaceuticals (Nasdaq: TNXP) will attend BTIG Infectious Disease Day 2026, holding virtual 1x1 investor meetings on June 16, 2026. President and CEO Seth Lederman, M.D., will participate. Tonix develops CNS and immunology treatments and advances several Phase 2 ready programs.
Positive
- None.
Negative
- None.
News Market Reaction – TNXP
On the day this news was published, TNXP declined 2.83%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $181.73M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Coverage expansion | Positive | +4.2% | Second commercial payer deal expanded TONMYA access to ~52M U.S. lives. |
| May 28 | Data presentation | Neutral | -2.5% | Real-world analysis of opioid/benzo use in fibromyalgia highlighted TONMYA launch. |
| May 27 | Clinical data | Positive | -4.9% | Phase 1 TNX-1500 data showed good tolerability and immunologic activity. |
| May 26 | Outcomes research | Neutral | +0.0% | Claims analysis quantified high healthcare use in fibromyalgia patients. |
| May 14 | Conference preview | Positive | +1.8% | Announcement of upcoming ISPOR poster linked to TONMYA’s approval and launch. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company and clinical updates often drew mixed reactions, with positive clinical news sometimes met with negative price moves, but commercial progress for TONMYA tending to align with gains.
Over the past month, Tonix reported several developments across commercial and clinical fronts. On Jun 08, expanded commercial coverage for TONMYA coincided with a +4.16% move, while multiple May real-world fibromyalgia analyses highlighted disease burden and the recent U.S. launch. Positive Phase 1 data for TNX-1500 on May 27 saw a -4.86% reaction, showing that clinical progress has not always been rewarded. Today’s conference participation update fits within this ongoing visibility and outreach effort.
Key Terms
sublingual medical
monoclonal antibody medical
cd40 ligand (cd40l) inhibitor medical
intranasal medical
phase 2 medical
prader-willi syndrome medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, today announced that the management team will participate in 1x1 meetings at BTIG’s Infectious Disease Day 2026, held virtually on June 16, 2026.
BTIG Infectious Disease Day 2026
Participant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Location: Virtual
Date: June 16, 2026
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD154/CD40 ligand (CD40L) inhibitor for the prevention of kidney transplant rejection. In addition, Tonix is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com.
*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Contacts
Deborah Elson (Investors/Media)
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
investor.relations@tonixpharma.com
Brian Korb (Investors)
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Ray Jordan (Media)
Putnam Insights
ray@putnaminsights.com
